Trial · NCT02795767
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
NCT02795767, Phase 3, Completed, Hoffmann-La Roche; results first posted 2019-04-10
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors. Trials, record NCT02795767. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02795767
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
- NCT number
- NCT02795767
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 88 participants, actual
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Hemophilia A
- Interventions
- Emicizumab
- First posted
- 2016-06-10
- Last updated
- 2021-06-02
- Other registries' IDs
- eudract:2016-000073-21
- Results first posted
- 2019-04-10
Source ClinicalTrials.gov
Registered outcomes70
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | The number of treated bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded. |
| Primary | Cohort A: Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | The number of all bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in followup times (i.e., the time that each participant stays in the study). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the "treated bleeds" outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself. |
| Primary | Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | The number of treated spontaneous bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A bleed is classified as "spontaneous" if there is no other known contributing factor such as trauma or procedure/surgery. A "treated spontaneous bleed" is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded. |
| Primary | Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | The number of treated joint bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A "joint bleed" is defined as a bleed with type reported as "joint" and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A "treated joint bleed" is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Only treated bleeds that fulfilled the 72-hour rule were included in the analysis of treated joint bleeds, excluding bleeds due to surgery/procedure. |
| Primary | Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | The number of treated target joint bleeds over the efficacy period is presented here as a model-based ABR that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A "target joint bleed" is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A "treated target joint bleed" is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded. |
| Primary | Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded. |
| Primary | Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the "treated bleeds" outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself. |
| Primary | Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A bleed is classified as "spontaneous" if there is no other known contributing factor such as trauma or procedure/surgery. A "treated spontaneous bleed" is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded. |
| Primary | Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A "joint bleed" is defined as a bleed with type reported as "joint" and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A "treated joint bleed" is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Only treated bleeds that fulfilled the 72-hour rule were included in the analysis of treated joint bleeds, excluding bleeds due to surgery/procedure. |
| Primary | Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A "target joint bleed" is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A "treated target joint bleed" is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded. |
1 to 10 of 70Source ClinicalTrials.gov
See all 70 registered outcomesOutcomes70
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | All treated participants in Cohort A who were on the same dose of emicizumab for at least 12 weeks and were \<12 years of age | treated bleed rate per year | NUMBER |
| PRIMARY | Cohort A: Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | All treated participants in Cohort A who were on the same dose of emicizumab for at least 12 weeks and were \<12 years of age | all bleed rate per year | NUMBER |
| PRIMARY | Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | All treated participants in Cohort A who were on the same dose of emicizumab for at least 12 weeks and were \<12 years of age | treated spontaneous bleed rate per year | NUMBER |
| PRIMARY | Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | All treated participants in Cohort A who were on the same dose of emicizumab for at least 12 weeks and were \<12 years of age | treated joint bleed rate per year | NUMBER |
| PRIMARY | Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | All treated participants in Cohort A who were on the same dose of emicizumab for at least 12 weeks and were \<12 years of age | treated target joint bleed rate per year | NUMBER |
| PRIMARY | Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | All treated participants in Cohort A who were on the same dose of emicizumab for at least 12 weeks and were \<12 years of age | treated bleed rate per year | MEAN |
| PRIMARY | Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | All treated participants in Cohort A who were on the same dose of emicizumab for at least 12 weeks and were \<12 years of age | all bleed rate per year | MEAN |
| PRIMARY | Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | All treated participants in Cohort A who were on the same dose of emicizumab for at least 12 weeks and were \<12 years of age | treated spontaneous bleed rate per year | MEAN |
| PRIMARY | Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | All treated participants in Cohort A who were on the same dose of emicizumab for at least 12 weeks and were \<12 years of age | treated joint bleed rate per year | MEAN |
| PRIMARY | Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants <12 Years of Age | From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks. | All treated participants in Cohort A who were on the same dose of emicizumab for at least 12 weeks and were \<12 years of age | treated target joint bleed rate per year | MEAN |
1 to 10 of 70Source ClinicalTrials.gov
See all 70 outcomesResults by group704
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants <12 Years of Age | Cohort A: 1.5 mg/kg Emicizumab QW | 0.3 | 95% Confidence Interval 0.17 to 0.50 | treated bleed rate per year | |
| Cohort A: Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants <12 Years of Age | Cohort A: 1.5 mg/kg Emicizumab QW | 3.2 | 95% Confidence Interval 1.94 to 5.22 | all bleed rate per year | |
| Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants <12 Years of Age | Cohort A: 1.5 mg/kg Emicizumab QW | 0.0 | 95% Confidence Interval 0.0 to 0.1 | treated spontaneous bleed rate per year | |
| Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants <12 Years of Age | Cohort A: 1.5 mg/kg Emicizumab QW | 0.2 | 95% Confidence Interval 0.08 to 0.29 | treated joint bleed rate per year | |
| Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants <12 Years of Age | Cohort A: 1.5 mg/kg Emicizumab QW | NA | 95% Confidence Interval NA to NA | treated target joint bleed rate per year | |
| Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants <12 Years of Age | Cohort A: 1.5 mg/kg Emicizumab QW | 0.3 | 95% Confidence Interval 0.00 to 4.31 | treated bleed rate per year | |
| Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for All Bleeds in Treated Participants <12 Years of Age | Cohort A: 1.5 mg/kg Emicizumab QW | 3.2 | 95% Confidence Interval 0.70 to 9.04 | all bleed rate per year | |
| Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds in Treated Participants <12 Years of Age | Cohort A: 1.5 mg/kg Emicizumab QW | 0.0 | 95% Confidence Interval 0.00 to 3.74 | treated spontaneous bleed rate per year | |
| Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Joint Bleeds in Treated Participants <12 Years of Age | Cohort A: 1.5 mg/kg Emicizumab QW | 0.2 | 95% Confidence Interval 0.00 to 4.01 | treated joint bleed rate per year | |
| Cohort A: Mean Calculated Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds in Treated Participants <12 Years of Age | Cohort A: 1.5 mg/kg Emicizumab QW | 0.1 | 95% Confidence Interval 0.00 to 3.84 | treated target joint bleed rate per year |
1 to 10 of 704Source ClinicalTrials.gov
See all 704 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort A: 1.5 mg/kg Emicizumab QW | 68 | |
| Overall Study | STARTED | Cohort B: 3 mg/kg Emicizumab Q2W | 10 | |
| Overall Study | STARTED | Cohort C: 6 mg/kg Emicizumab Q4W | 10 | |
| Overall Study | Received at Least One Dose of Emicizumab | Cohort A: 1.5 mg/kg Emicizumab QW | 68 | |
| Overall Study | Received at Least One Dose of Emicizumab | Cohort B: 3 mg/kg Emicizumab Q2W | 10 | |
| Overall Study | Received at Least One Dose of Emicizumab | Cohort C: 6 mg/kg Emicizumab Q4W | 10 | |
| Overall Study | Dose Up-Titrated to 3 mg/kg QW | Cohort A: 1.5 mg/kg Emicizumab QW | 0 | |
| Overall Study | Dose Up-Titrated to 3 mg/kg QW | Cohort B: 3 mg/kg Emicizumab Q2W | 0 | |
| Overall Study | Dose Up-Titrated to 3 mg/kg QW | Cohort C: 6 mg/kg Emicizumab Q4W | 3 | |
| Overall Study | Completed 52 Weeks in Study | Cohort A: 1.5 mg/kg Emicizumab QW | 67 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events261
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Cohort A: 1.5 mg/kg Emicizumab QW | 2 | 68 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort B: 3 mg/kg Emicizumab Q2W | 0 | 10 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort C: 6 mg/kg Emicizumab Q4W | 1 | 10 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Cohort A: 1.5 mg/kg Emicizumab QW | 4 | 68 | 4 |
| other | Abdominal pain | Gastrointestinal disorders | Cohort B: 3 mg/kg Emicizumab Q2W | 2 | 10 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | Cohort C: 6 mg/kg Emicizumab Q4W | 0 | 10 | 0 |
| other | Abdominal pain upper | Gastrointestinal disorders | Cohort A: 1.5 mg/kg Emicizumab QW | 4 | 68 | 6 |
| other | Abdominal pain upper | Gastrointestinal disorders | Cohort B: 3 mg/kg Emicizumab Q2W | 0 | 10 | 0 |
| other | Abdominal pain upper | Gastrointestinal disorders | Cohort C: 6 mg/kg Emicizumab Q4W | 1 | 10 | 1 |
| other | Constipation | Gastrointestinal disorders | Cohort A: 1.5 mg/kg Emicizumab QW | 4 | 68 | 4 |
1 to 10 of 261Source ClinicalTrials.gov
See all 261 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort A: 1.5 mg/kg Emicizumab QW | 0 | 68 |
| Total, all-cause mortality | Cohort B: 3 mg/kg Emicizumab Q2W | 0 | 10 |
| Total, all-cause mortality | Cohort C: 6 mg/kg Emicizumab Q4W | 0 | 10 |
| Total, other adverse events | Cohort A: 1.5 mg/kg Emicizumab QW | 64 | 68 |
| Total, other adverse events | Cohort B: 3 mg/kg Emicizumab Q2W | 9 | 10 |
| Total, other adverse events | Cohort C: 6 mg/kg Emicizumab Q4W | 10 | 10 |
| Total, serious adverse events | Cohort A: 1.5 mg/kg Emicizumab QW | 23 | 68 |
| Total, serious adverse events | Cohort B: 3 mg/kg Emicizumab Q2W | 1 | 10 |
| Total, serious adverse events | Cohort C: 6 mg/kg Emicizumab Q4W | 3 | 10 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02795767
GET https://conductscience.org/api/trials/v1/NCT02795767/registered?page=2